The Brucella abortus S19 δvjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle

Infection and Immunity

Volumn 77, Issue 2, 2009, Pages 877-884

  Arenas Gamboa, A M ^a   Ficht, T A ^a   Kahl McDonagh, M M ^a   Gomez, G ^a   Rice Ficht, A C ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; IMMUNOGLOBULIN G; LIVE VACCINE; MICROSPHERE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; VITELLIN; VITELLIN B; BRUCELLA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BRUCELLA ABORTUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENCAPSULATION; FASCIOLA HEPATICA; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLENOMEGALY; SUSTAINED DRUG RELEASE; VJBR GENE; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BRUCELLOSIS; DELAYED RELEASE FORMULATION; GENE DELETION; GENETICS; IMMUNOLOGY; MUTATION; PATHOLOGY; SPLEEN; STANDARD;

ANIMALS; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; DELAYED-ACTION PREPARATIONS; FEMALE; GENE DELETION; MICE; MICE, INBRED BALB C; MUTATION; SPLEEN;

EID: 60549100504     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01017-08     Document Type: Article

References (34)

1. Abraham, S. M., R. F. Vieth, and D. J. Burgess. 1996. Novel technology for the preparation of sterile alginate-poly-L-lysine microcapsules in a bioreactor. Pharm. Dev. Technol. 1:63-68.
2. Allen, C. A., L. G. Adams, and T. A. Ficht. 1998. Transposon-derived Brucella abortus rough mutants are attenuated and exhibit reduced intracellular survival. Infect. Immun. 66:1008-1016.
3. Allsup, T. N. 1969. Abortion in sheep associated with Brucella abortus infection. Vet. Rec. 84:104-108.
4. Arenas-Gamboa, A. M., T. A. Ficht, M. M. Kahl-McDonagh, and A. C. Rice-Ficht. 2008. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect. Immun. 76:2448-2455.
5. Boschiroli, M. L., V. Foulongne, and D. O'Callaghan. 2001. Brucellosis: a worldwide zoonosis. Curr. Opin. Microbiol. 4:58-64.
6. Cieslak, T. J., G. W. Christopher, M. G. Kortepeter, J. R. Rowe, J. A. Pavlin, R. C. Culpepper, and E. M. Eitzen, Jr. 2000. Immunization against potential biological warfare agents. Clin. Infect. Dis. 30:843-850.
7. Davis, D. S., and P. H. Elzer. 2002. Brucella vaccines in wildlife. Vet. Microbiol 90:533-544
8. Delrue, R. M., C. Deschamps, S. Leonard, C. Nijskens, I. Danese, J. M. Schaus, S. Bonnot, J. Ferooz, A. Tibor, X. De Bolle, and J. J. Letesson. 2005. A quorum-sensing regulator controls expression of both the type IV secretion system and the flagellar apparatus of Brucella melitensis. Cell. Microbiol. 7:1151-1161.
9. Estevan, M., C. Gamazo, G. Gonzalez-Gaitano, and J. M. Irache. 2006. Optimization of the entrapment of bacterial cell envelope extracts into microparticles for vaccine delivery. J. Microencapsul. 23:169-181.
10. Estevan, M., C. Gamazo, F. Martinez-Galan, and J. M. Irache. 16 October 2008, posting date. Stability of poly(e-caprolactone) microparticles containing Brucella ovis antigens as a vaccine delivery system against brucellosis. AAPS PharmSciTech. doi:10.1208/s12249-008-9149-2.
11. Estevan, M., J. M. Irache, M. J. Grillo, J. M. Blasco, and C. Gamazo. 2006. Encapsulation of antigenic extracts of Salmonella enterica serovar: Abortusovis into polymeric systems and efficacy as vaccines in mice. Vet. Microbiol. 118:124-132.
12. Eyles, J. E., Z. C. Carpenter, H. O. Alpar, and E. D. Williamson. 2003. Immunological aspects of polymer microsphere vaccine delivery systems. J. Drug Target. 11:509-514.
13. Hong, P. C., R. M. Tsolis, and T. A. Ficht. 2000. Identification of genes required for chronic persistence of Brucella abortus in mice. Infect. Immun. 68:4102-4107.
14. Jones, D. H. 2003. Microencapsulation of vaccine antigens. Methods Mol. Med. 87:211-222.
15. Kahl-McDonagh, M. M., and T. A. Ficht. 2006. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect. Immun. 74:4048-4057.
16. Lameiro, M. H., R. Malpique, A. C. Silva, P. M. Alves, and E. Melo. 2006. Encapsulation of adenoviral vectors into chitosan-bile salt microparticles for mucosal vaccination. J. Biotechnol. 126:152-162.
17. Lima, K. M., and J. M. Rodrigues Junior. 1999. Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system. Braz. J. Med. Biol. Res. 32:171-180.
18. Lin, J. H., C. N. Weng, C. W. Liao, K. S. Yeh, and M. J. Pan. 2003. Protective effects of oral microencapsulated Mycoplasma hyopneumoniae vaccine prepared by co-spray drying method. J. Vet. Med. Sci. 65:69-74.
19. Mahajan, N. K., R. C. Kulshrestha, and B. Vasudevan. 1986. Brucellosis- cause of abortion in sheep and its public health significance. Int. J. Zoonoses 13:174-179.
20. Malyala, P., J. Chesko, M. Ugozzoli, A. Goodsell, F. Zhou, M. Vajdy, D. T. O'Hagan, and M. Singh. 2008. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J. Pharm. Sci. 97:1155-1164.
21. Murillo, M., C. Gamazo, J. M. Irache, and M. M. Goni. 2002. Polyester microparticles as a vaccine delivery system for brucellosis: influence of the polymer on release, phagocytosis and toxicity. J. Drug Target. 10:211-219.
22. Nicoletti, P. 1990. Vaccination against Brucella. Adv. Biotechnol. Processes 13:147-168.
23. Pappas, G., N. Akritidis, M. Bosilkovski, and E. Tsianos. 2005. Brucellosis. N. Engl. J. Med. 352:2325-2336.
24. Pei, J., and T. A. Ficht. 2004. Brucella abortus rough mutants are cytopathic for macrophages in culture. Infect. Immun. 72:440-450.
25. Rice-Ficht, A. C., K. A. Dusek, G. J. Kochevar, and J. H. Waite. 1992. Eggshell precursor proteins of Fasciola hepatica. I. Structure and expression of vitelline protein B. Mol. Biochem. Parasitol. 54:129-141.
26. Schurig, G. G., N. Sriranganathan, and M. J. Corbel. 2002. Brucellosis vaccines: past, present and future. Vet. Microbiol. 90:479-496.
27. Stevens, M. G., S. C. Olsen, G. W. Pugh, Jr., and D. Brees. 1995. Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51. Infect. Immun. 63:264-270.
28. Stuart, F. A., M. J. Corbel, and R. A. Brewer. 1987. Experimental Brucella abortus infection in pigs. Vet. Microbiol. 14:365-379.
29. Sun, H., K. G. Pollock, and J. M. Brewer. 2003. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21:849-855.
30. Waite, J. H., and A. C. Rice-Ficht. 1992. Eggshell precursor proteins of Fasciola hepatica. II. Microheterogeneity in vitelline protein B. Mol. Bio-chem. Parasitol. 54:143-151.
31. Wang, F., X. W. He, L. Jiang, D. Ren, Y. He, D. A. Li, and S. H. Sun. 2006. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice. Vaccine 24:2017-2026.
32. Wee, S., and W. R. Gombotz. 1998. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31:267-285.
33. + T cells by Brucella infection or immunization with antigenic extracts. Infect. Immun. 63:969-975.
34. Zwiorek, K., C. Bourquin, J. Battiany, G. Winter, S. Endres, G. Hartmann, and C. Coester. 2008. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res. 25:551-562.